Trevi Therapeutics (TRVI) Price & Analysis

Compare

542 Followers

TRVI Stock Chart & Stats

Day’s Range― - ―

52-Week Range$2.36 - $9.92

Previous CloseN/A

Volume226.18K

Average Volume (3M)2.54M

Market Cap

$971.78M

Enterprise Value$510.02M

Total Cash (Recent Filing)$203.88M

Total Debt (Recent Filing)$891.00K

Price to Earnings (P/E)―

Beta0.15

Next Earnings

Nov 05, 2025

EPS Estimate

-0.1

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.09

Shares Outstanding121,776,855

10 Day Avg. Volume3,725,611

30 Day Avg. Volume2,537,897

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)N/A

Price to Sales (P/S)N/A

P/FCF RatioN/A

Enterprise Value/Market Cap0.52

Enterprise Value/Revenue3.49K

Enterprise Value/Gross Profit-13.42K

Enterprise Value/Ebitda-10.24

Forecast

1Y Price Target

$20.22

Price Target Upside136.77% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering9

Bulls Say, Bears Say

Bulls Say

Clinical DevelopmentHaduvio has demonstrated impressive placebo-adjusted reductions in cough across multiple clinical studies, suggesting it could be a superior treatment option.

Market ExpansionTRVI's conviction in the non-IPF cough ILD indication is seen as a positive as approval in ILD cough broadly could significantly increase the total addressable market for Haduvio.

Product PotentialTrevi's Haduvio is seen as a multi-billion dollar opportunity, addressing significant treatment gaps in chronic cough.

Bears Say

Clinical TrialsPh1 studies evaluating Haduvio impact on respiratory function in IPF and potential drug-drug interaction are underway, and these datasets are expected to be favorable.

Regulatory ChallengesThe company anticipates moving towards Phase 3 initiation in IPF, contingent on results from the respiratory depression study and an end-of-Phase-2 meeting with the FDA.

Trevi Therapeutics News

CoreWeave upgraded, Instacart downgraded: Wall Street’s top analyst calls

The most talked about and market moving research calls around Wall Street are now in one place. Here...

29d ago

ALC

Trevi Therapeutics initiated with an Overweight at Morgan Stanley

Morgan Stanley analyst Judah Frommer initiated coverage of Trevi Therapeutics (TRVI) with an Overweight rating and $18 price...

30d ago

TRVI

Trevi Therapeutics: Buy Rating Affirmed Amid Promising Haduvio Trial Data and Strategic Market Expansion

Analyst Debanjana Chatterjee of JonesTrading maintained a Buy rating on Trevi Therapeutics, retaining the price target of $25.00....

12h ago

TRVI

Trevi Therapeutics CFO Resignation Announced

Trevi Therapeutics ( ($TRVI) ) has issued an announcement. On August 14, 2025, Trevi Therapeutics announced that its...

1M ago

TRVI

Trevi Therapeutics: Optimism Amid Earnings Call Insights

Trevi Therapeutics (($TRVI)) has held its Q2 earnings call. Read on for the main highlights of the call....

1M ago

TRVI

Promising Developments and Strategic Expansion Bolster Trevi Therapeutics’ Growth Potential

Analyst Debanjana Chatterjee from JonesTrading reiterated a Buy rating on Trevi Therapeutics and keeping the price target at...

1M ago

TRVI

Trevi Therapeutics price target lowered to $27 from $29 at Raymond James

Raymond James lowered the firm’s price target on Trevi Therapeutics (TRVI) to $27 from $29 and keeps a...

1M ago

TRVI

Promising Phase 2b Results and Strong Financial Position Drive Buy Rating for Trevi Therapeutics

Trevi Therapeutics, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Brandon Folkes from...

1M ago

TRVI

Trevi Therapeutics Reports Positive Trial Results and Financial Stability

Trevi Therapeutics ( ($TRVI) ) has released its Q2 earnings. Here is a breakdown of the information Trevi...

1M ago

TRVI

Trevi Therapeutics reports Q2 EPS (9c), consensus (10c)

Ended Q2 with $203.9M in cash, cash equivalents and marketable securities, with expected cash runway into 2029. “The...

1M ago

TRVI

Trevi Therapeutics initiated with an Overweight at Cantor Fitzgerald

Cantor Fitzgerald initiated coverage of Trevi Therapeutics (TRVI) with an Overweight rating and $25 price target Cantor tells...

3M ago

TRVI

Trevi Therapeutics initiated with an Overweight at Cantor Fitzgerald

Cantor Fitzgerald initiated coverage of Trevi Therapeutics (TRVI) with an Overweight rating and $25 price target Published first...

3M ago

TRVI

Trevi Therapeutics Stockholders Approve Key Amendments

Trevi Therapeutics ( ($TRVI) ) just unveiled an announcement. On June 11, 2025, Trevi Therapeutics, Inc. held its...

3M ago

TRVI

Trevi Therapeutics: Positive Developments and Financial Strength Support Buy Rating

Leerink Partners analyst Faisal Khurshid reiterated a Buy rating on Trevi Therapeutics (TRVI – Research Report) on June...

3M ago

TRVI

TRVI FAQ

What was Trevi Therapeutics Inc’s price range in the past 12 months?

Trevi Therapeutics Inc lowest stock price was $2.36 and its highest was $9.92 in the past 12 months.

What is Trevi Therapeutics Inc’s market cap?

Trevi Therapeutics Inc’s market cap is $971.78M.

When is Trevi Therapeutics Inc’s upcoming earnings report date?

Trevi Therapeutics Inc’s upcoming earnings report date is Nov 05, 2025 which is in 47 days.

How were Trevi Therapeutics Inc’s earnings last quarter?

Trevi Therapeutics Inc released its earnings results on Aug 07, 2025. The company reported -$0.09 earnings per share for the quarter, beating the consensus estimate of -$0.104 by $0.014.

Is Trevi Therapeutics Inc overvalued?

According to Wall Street analysts Trevi Therapeutics Inc’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Trevi Therapeutics Inc pay dividends?

Trevi Therapeutics Inc does not currently pay dividends.

What is Trevi Therapeutics Inc’s EPS estimate?

Trevi Therapeutics Inc’s EPS estimate is -0.1.

How many shares outstanding does Trevi Therapeutics Inc have?

Trevi Therapeutics Inc has 121,776,855 shares outstanding.

What happened to Trevi Therapeutics Inc’s price movement after its last earnings report?

Trevi Therapeutics Inc reported an EPS of -$0.09 in its last earnings report, beating expectations of -$0.104. Following the earnings report the stock price went up 1.644%.

Which hedge fund is a major shareholder of Trevi Therapeutics Inc?

Currently, no hedge funds are holding shares in TRVI

Trevi Therapeutics Stock Smart Score

Outperform

Fundamentals

Return on Equity

-35.74%

Trailing 12-Months

Asset Growth

182.26%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Trevi Therapeutics Inc

Trevi Therapeutics (TRVI) is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for the treatment of serious neurological conditions. The company's lead product candidate, Haduvio, is being developed for the treatment of chronic pruritus (itch), and chronic cough in adults with idiopathic pulmonary fibrosis (IPF). Trevi Therapeutics operates within the biotechnology and pharmaceutical sectors, aiming to address unmet medical needs in these niche markets.

Trevi Therapeutics (TRVI) Earnings & Revenues

Historic Earnings Reports

TRVI Earnings Call

Q2 2025

0:00 / 0:00

Earnings Call Sentiment|Positive

The earnings call was largely positive, highlighting successful trial results, a strong financial position, and clear plans for future clinical development. While there were increased expenses and a reported net loss, these were balanced by significant achievements and forward-looking strategies.View all TRVI earnings summaries

TRVI Stock 12 Month Forecast

Average Price Target

$20.22

▲(136.77% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"1":"$1","28":"$28","7.75":"$7.75","14.5":"$14.5","21.25":"$21.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":27,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$27.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":20.22,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$20.22</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":13,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$13.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[1,7.75,14.5,21.25,28],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Dec<br/>2024","6":"Mar<br/>2025","9":"Jun<br/>2025","12":"Sep<br/>2025","25":"Sep<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,7.27,8.787692307692307,10.305384615384614,11.823076923076922,13.34076923076923,14.858461538461537,16.376153846153848,17.893846153846155,19.411538461538463,20.92923076923077,22.446923076923078,23.964615384615385,25.482307692307693,{"y":27,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,7.27,8.266153846153845,9.262307692307692,10.258461538461537,11.254615384615384,12.25076923076923,13.246923076923075,14.243076923076922,15.239230769230769,16.235384615384614,17.23153846153846,18.22769230769231,19.223846153846154,{"y":20.22,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,7.27,7.71076923076923,8.151538461538461,8.592307692307692,9.033076923076923,9.473846153846154,9.914615384615384,10.355384615384615,10.796153846153846,11.236923076923077,11.677692307692308,12.118461538461538,12.55923076923077,{"y":13,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":3.16,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.11,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.01,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.86,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 29,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.12,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.94,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.52,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.01,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.9,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 32,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.32,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.7,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.33,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.27,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >